Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

n-GAAP earnings are projected

to rise to approximately $7.00 per diluted share by 2011.

-- Myozyme sales are expected to be approximately $275-$285 million this

year, compared to prior guidance of $320-$330 million.

-- Non-GAAP earnings per share for the second quarter are expected to be

in the mid $0.90s, reflecting ongoing investments to drive future

growth. These include investments in the U.S. launch of Renvela(R)

(sevelamer carbonate) and the expanded European introduction of

Clolar(R) (clofarabine), as well as investments in late-stage clinical

trials-particularly the phase 3 study of alemtuzumab for multiple

sclerosis. This estimate also reflects the constraints on U.S. Myozyme

sales.

First-Quarter Product Sales

-- Within the Therapeutics business, worldwide demand for Myozyme remains

robust two years into the product's launch. First-quarter sales rose

78 percent despite the delay in U.S. approval for 2000L production

capacity. Sales increased to $67.3 million from $37.9 million in the

period a year ago, driven by the number of new patients starting

therapy. As announced, the FDA will require Genzyme to submit a BLA to

obtain U.S. commercial approval for Myozyme produced at the 2000L

scale. The agency is expected to act on the application by the end of

this year.

-- First-quarter sales of Cerezyme(R) (imiglucerase for injection) rose 15

percent to $304.3 million, compared with $263.8 million in the previous

first quarter.

-- Sales of Fabrazyme(R) (agalsidase beta) grew 16 percent in the quarter,

rising to $116.5 million from $100.7 million in the first quarter last

year. Fabrazyme has captured more than a two thirds share of the

international market for Fabry disease treatment based on compelling

clinical dat
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Applied DNA Sciences, Inc. (OTCQB: ... and product authentication solutions, will host a conference call ... third quarter results. The Quarterly Report on Form 10Q ... of the day on Monday August 11, 2014. ... conference call beginning at 9:00 A.M. Eastern Daylight Time ...
(Date:8/1/2014)... August 01, 2014 RURO, Inc., ... provider, today officially announces the opening of its ... Science Park, Baoshan District in Shanghai, PRC, RURO ... under the management of Mr. Shen Gang, the ... the past three years, RURO’s has installed FreezerPro-based ...
(Date:8/1/2014)... , Aug. 1, 2014 One of the ... of personalized medicine, which is the practice of using ... to a patient,s individual biology. Personalized diagnostics—laboratory analyses that ... role in the lab,s future. This fall, AACC ... the latest science in this exciting field and the ...
(Date:8/1/2014)... Research and Markets has announced the addition ... and Analysis Market 2014-2018" report to their offering. ... Single Nucleotide Polymorphism (SNP) genotyping is the screening and ... of various species. SNPs are commonly present in all ... analyze thousands of SNPs and has the potential for ...
Breaking Biology Technology:Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 2Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014 3RURO Opens Office in Shanghai, China 2First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Single Nucleotide Polymorphism (SNP) Genotyping and Analysis Market 2014-2018 2
... COLUMBIA, Md., Dec. 14 A&G Pharmaceutical announced,today ... Initiative,has awarded A&G an $870,000 grant to conduct ... proprietary breast cancer biomarker,GP88, in blood and tissue ... could provide the basis for developing a blood ...
... Embla Systems, a leader in the field of,sleep ... of an,exclusive agreement with the Beth Israel Deaconess ... Pulmonary Coupling (CPC) technology,developed by Drs. Robert Thomas, ... CPC technology represents a breakthrough in how sleep ...
... New Mexico, December 13, 2007In collaboration with the ... international team of researchers has, for the first ... mysterious metallic puddles that facilitate the transition of ... one. , The research may lead to a ...
Cached Biology Technology:A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 2A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer 3Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 2Collaboration yields 'the right glasses' for observing mystery behavior in electrons 3
(Date:8/1/2014)... Charan Ranganath of the UC Davis Center for ... National Security Science and Engineering Faculty Fellowship from ... million fellowship will support new work on learning ... UC Davis. , The new project aims to ... with activity in the cortex and hippocampus, brain ...
(Date:8/1/2014)... is tricky enough. Knowing what causes them at the ... of Iowa researchers have created the most detailed map ... long associated with blinding diseases, such as age-related macular ... in the choroid, which supplies blood and oxygen to ... differences in the abundance of proteins in different areas ...
(Date:8/1/2014)... 2014 The Journal of Nutrition Education and Behavior ... Educational Material (GEM) awards, which were presented at the ... "Nutrition Education Impact: Local to Global," in Milwaukee, Wisconsin, ... awards recognize the authors of the best article and ... by members of the JNEB Journal Committee and Board ...
Breaking Biology News(10 mins):A map for eye disease 2
... and Avalon Technology partner on new ... aviation-related ... Inc.,(OTC Bulletin Board: CTHH) ( http://www.catcherinc.com ), a leader ... Technology ( http://www.avalontechnology.com ), a leading,integrator of managed mobile ...
... resulting from higher CO2 could boost the amount ... new study looks at a poorly understood process ... Sayer, postdoctoral fellow at the Smithsonian Tropical Research ... University of Minnesotas Department of Ecology, Evolution and ...
... Boulder, CO, USA Two hundred years ago Lewis and ... deal of scientific research with its descriptions of territory acquired ... be disappointed by the absence of living megafauna, the area ... volume published by the Geological Society of America makes clear ...
Cached Biology News:CATCHER to be Deployed at Major U.S. Airline 2CATCHER to be Deployed at Major U.S. Airline 3CATCHER to be Deployed at Major U.S. Airline 4Complex carbon picture clearer 2
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Anti-BAR Immunogen: Peptide of aa 3-21 from human Bar Available Date: 38226...
... the HECT protein, E6-AP and ... suggests that this E2 is ... of non-""N-end rule"" protein substrates ... proteins as well as the ...
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Biology Products: